Lobbying client
EDISON PHARMACEUTICALS
Drug development for treatment of rare mitochondrial disease, TBI, and TON
Filings
11
Filed by
1
Reported in-house
—
Reported by firms
$80,000
Reported lobbying by year
The larger of in-house and firm-reported each year, $ thousands
2011 to 2012
Filings
11 filings, newest first.
| Filing | Filed by | Amount |
|---|---|---|
|
4th Quarter - Termination Amendment 4th Quarter 2012
|
FABIANI & COMPANY | — reported |
|
4th Quarter - Termination (No Activity)replaced 4th Quarter 2012
|
FABIANI & COMPANY | — reported |
|
3rd Quarter - Report (No Activity) 3rd Quarter 2012
|
FABIANI & COMPANY | — reported |
|
2nd Quarter - Report (No Activity) 2nd Quarter 2012
|
FABIANI & COMPANY | $20,000 reported |
|
1st Quarter - Report 1st Quarter 2012
|
FABIANI & COMPANY | $20,000 reported |
|
Registration - Amendment 1st Quarter 2011
|
FABIANI & COMPANY | — reported |
|
4th Quarter - Report 4th Quarter 2011
|
FABIANI & COMPANY | $40,000 reported |
|
3rd Quarter - Report 3rd Quarter 2011
|
FABIANI & COMPANY | — reported |
|
2nd Quarter - Report 2nd Quarter 2011
|
FABIANI & COMPANY | — reported |
|
1st Quarter - Report 1st Quarter 2011
|
FABIANI & COMPANY | — reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| FABIANI & COMPANY | 8 | $80,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Defense | DEF | 7 |
| Health Issues | HCR | 7 |
| Medical/Disease Research/Clinical Labs | MED | 1 |
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.